Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 12/20 | 0.62 |
| ▸ | CTSK | P43235 | 10/20 | 0.62 |
| ▸ | CTSB | P07858 | 3/20 | 0.62 |
| ▸ | CTSL | P07711 | 1/20 | 0.62 |
| ▸ | KLK5 | Q9Y337 | 3/20 | 0.61 |
| ▸ | ATM | Q13315 | 1/20 | 0.52 |
| ▸ | PSEN1 | P49768 | 3/20 | 0.52 |
| ▸ | PSEN2 | P49810 | 3/20 | 0.52 |
| ▸ | APH1B | Q8WW43 | 3/20 | 0.52 |
| ▸ | NCSTN | Q92542 | 3/20 | 0.52 |
| ▸ | APH1A | Q96BI3 | 3/20 | 0.52 |
| ▸ | PSENEN | Q9NZ42 | 3/20 | 0.52 |
| ▸ | APP | P05067 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4040240 | 1.00 | CTSS (0.62) | CTSSCTSKCTSBCTSLKLK5 | |
| SCHEMBL1601944 | 0.89 | CTSS (0.55) | CTSSCTSKCTSBCTSLKLK5 | |
| SCHEMBL7392856 | 0.86 | KLK5 (0.67) | CTSSCTSKCTSBCTSLKLK5 | |
| SCHEMBL7297673 | 0.85 | CTSS (0.61) | CTSSCTSKCTSBCTSLKLK5 | |
| SCHEMBL9516143 | 0.85 | CTSS (0.61) | CTSSCTSKCTSBCTSLKLK5 | |
| SCHEMBL15776419 | 0.85 | CTSS (0.61) | CTSSCTSKCTSBCTSLKLK5 | |
| SCHEMBL6345082 | 0.85 | CTSS (0.61) | CTSSCTSKCTSBCTSLKLK5 | |
| SCHEMBL7297668 | 0.85 | CTSS (0.61) | CTSSCTSKCTSBCTSLKLK5 | |
| SCHEMBL12751287 | 0.85 | KLK5 (0.66) | CTSSCTSKCTSBCTSLKLK5 | |
| SCHEMBL13328536 | 0.85 | KLK5 (0.66) | CTSSCTSKCTSBCTSLKLK5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7612054-B2 | Dibenzo[b,f]oxepine-10-carboxamides and pharmaceutical uses thereof | NOVARTIS AG (CH) | 2009-11-03 | — | — | US | disclosed |
| EP-1651592-B1 | NOVEL DIBENZO[B,F]OXEPINE-10-CARBOXAMIDES AND PHARMACEUTICAL USES THEREOF | NOVARTIS AG (CH) | 2009-04-29 | — | — | EP | disclosed |
| US-20070111991-A1 | Novel dibenzo [b, f] oxepine-10-carboxamides and pharmaceutical uses thereof | NOVARTIS AG (CH) | 2007-05-17 | — | — | US | disclosed |
| EP-1651592-A2 | NOVEL DIBENZO[B,F]OXEPINE-10-CARBOXAMIDES AND PHARMACEUTICAL USES THEREOF | Novartis AG (CH) | 2006-05-03 | — | — | EP | disclosed |
| WO-2005014517-A2 | NOVEL DIBENZO[B,F]OXEPINE-10-CARBOXAMIDES AND PHARMACEUTICAL USES THEREOF | NOVARTIS AG (CH) | 2005-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070111991-A1 | Novel dibenzo [b, f] oxepine-10-carboxamides and pharmaceutical uses thereof | APP, BACE1, BCHE | CTSS 2096/4885CTSK 2125/4885CTSB 1017/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.